Question explored with the scientific record
Side effects of flu jab
The short version: the flu shot has real, documented side effects, from common injection-site pain to rare but serious autoimmune events like Guillain-Barré syndrome, and the evidence base is weaker than most people are told.
The most common side effects are injection-site pain, headache, and fatigue. A 2023 overview of systematic reviews found that quadrivalent flu vaccines cause injection-site pain in about 1 in 10 more recipients than trivalent ones [13]. Allergic reactions, including anaphylaxis, are reported at a rate of about 2.4 per 100,000 doses in Australian surveillance [7]. A 2017 VAERS study of the recombinant flu vaccine listed anaphylaxis, rashes, and Parsonage-Turner syndrome (a rare nerve disorder) among the serious reports [8]. Shoulder injury from improper injection, specifically subdeltoid bursitis, was confirmed in a 2020 study of nearly 3 million vaccinations: about 16 cases occurred in the risk window versus 51 in the control window, a small but real risk [4].
The most studied serious side effect is Guillain-Barré syndrome (GBS), a paralytic nerve condition. The 1976 swine flu vaccine caused about 5-12 extra GBS cases per million doses [12]. For modern seasonal flu vaccines, the risk is much smaller but still measurable. A 2012 self-controlled analysis of the 2009 H1N1 vaccine found about 1.5-2.8 extra GBS cases per million doses [9]. A 1998 NEJM study of the 1992-1994 vaccines found an adjusted relative risk of 1.7, or about 1 extra case per million [10]. A 2022 VAERS analysis also found a significant signal for acute disseminated encephalomyelitis (ADEM), another autoimmune brain condition, particularly with cell-based flu vaccines [3].
The evidence has serious gaps. Most safety data comes from passive surveillance systems like VAERS, which detect only a fraction of real events. The most informative study design—comparing vaccinated people to truly unvaccinated people over time—is almost never run. The 2009 claims-based study [1] and the 2009 long-term care investigation [2] both had small numbers and wide confidence intervals. The 2013 Kaiser study claiming "no association" with GBS [11] compared vaccinated to vaccinated, a design that can hide real risks. The 2018 drug-interaction study [5] found cases of permanent disability after flu shots given with statins, but the sample was tiny.
The benefit side is also weaker than advertised. The 2019 IVVE trial design [6] for heart failure patients uses a placebo control, which is rare and commendable, but its results are not yet in the evidence here. Most flu vaccine studies use antibody titers as a surrogate endpoint, not hard outcomes like hospitalization or death. A rise in antibodies is not proof of protection.
| Side Effect | Approximate Risk | Source |
|---|---|---|
| Injection-site pain (QIV vs TIV) | ~10% relative increase | [13] |
| Allergic reaction (any) | ~2.4 per 100,000 doses | [7] |
| Subdeltoid bursitis | ~16 cases per 3 million doses | [4] |
| Guillain-Barré (modern seasonal) | ~1 extra case per million doses | [9, 10] |
| Guillain-Barré (1976 swine flu) | 5-12 extra cases per million | [12] |
| ADEM (autoimmune brain inflammation) | Signal detected, rate not given | [3] |
My call: the flu shot carries a small but real risk of serious autoimmune side effects, especially GBS, and the evidence for its benefits in healthy adults is built on surrogate endpoints and manufacturer-funded studies. For elderly or high-risk individuals, the risk-benefit may tip differently, but the data is too thin to say with confidence. Confidence: moderate that the risks are real but small; low that the benefits outweigh them for most healthy people.
Sources used 13
-
Active Influenza Vaccine Safety Surveillance
This study assesses the feasibility of using healthcare claims data for rapid detection of adverse events following influenza vaccination during the 2006-2007 season, suggesting that administrative claims data could enhance vaccine safety surveillance, especially during pandemic…
DOI: 10.1097/mlr.0b013e3181b58b5c -
Death and serious illness following influenza vaccination: a multidisciplinary investigation
This study investigates the potential association between influenza vaccination and subsequent deaths and serious illnesses among elderly residents in a long-term care facility, finding no significant evidence linking the vaccine to these adverse events.
DOI: 10.1002/pds.1743 -
Association between seasonal influenza vaccines and the increased risk of acute disseminated encephalomyelitis, estimated using the Vaccine Adverse Event Reporting System
This study found a significant association between seasonal influenza vaccines and reported acute disseminated encephalomyelitis (ADEM) cases in the US VAERS database from 2011–2020, with a higher reporting odds ratio for cell-based vaccines and differential time-to-onset profil…
DOI: 10.31083/ph.2022.2354 -
Risk for Subdeltoid Bursitis After Influenza Vaccination
This population-based cohort study estimates the risk of subdeltoid bursitis following influenza vaccination, finding a significant but small absolute risk associated with the vaccine.
DOI: 10.7326/m19-3176 -
No signal of interactions between influenza vaccines and drugs used for chronic diseases: a case-by-case analysis of the vaccine adverse event reporting system and vigibase
This study investigates the potential interactions between influenza vaccines and chronic disease medications, analyzing adverse event reports to assess the safety and implications of such interactions.
DOI: 10.1080/14760584.2018.1442718 -
Randomized controlled trial of influenza vaccine in patients with heart failure to reduce adverse vascular events (IVVE): Rationale and design
A large multicenter, randomized, placebo-controlled trial to determine whether annual inactivated influenza vaccination reduces major adverse vascular events in adults with heart failure over three influenza seasons.
DOI: 10.1016/j.ahj.2019.02.009 -
Allergic adverse events following 2015 seasonal influenza vaccine, Victoria, Australia
A Victorian surveillance study of allergy-related adverse events following the 2015 seasonal influenza vaccine found a higher proportion of allergy-related AEFI but no overall increase in adverse events, suggesting vaccine-strain–related variability in reactogenicity and undersc…
DOI: 10.2807/1560-7917.es.2017.22.20.30535 -
Postmarketing safety surveillance of trivalent recombinant influenza vaccine: Reports to the Vaccine Adverse Event Reporting System
This study reviews and summarizes reports of adverse events following the administration of the trivalent recombinant influenza vaccine (RIV3) to improve understanding of its safety profile, revealing that allergic reactions, including anaphylaxis, were the most common adverse e…
DOI: 10.1016/j.vaccine.2017.08.047 -
The Risk of Guillain–Barré Syndrome Associated with Influenza A (H1N1) 2009 Monovalent Vaccine and 2009–2010 Seasonal Influenza Vaccines: Results from Self‐Controlled Analyses
Self-controlled analyses of vaccinated GBS cases found a small, measurable excess of Guillain-Barré syndrome in the 42 days after 2009 H1N1 vaccination (variable-window RR 2.1, fixed-window RR 3.0; about 1.5-2.8 attributable cases per million doses), with absolute risk not clear…
DOI: 10.1002/pds.3220 -
The Guillain–Barré Syndrome and the 1992–1993 and 1993–1994 Influenza Vaccines
In four U.S. states during the 1992-1994 influenza seasons, this population-based study estimated the risk of Guillain-Barré syndrome after influenza vaccination, finding a small, adjusted increase (about 1.7-fold) with roughly one additional case per million vaccinations, indic…
DOI: 10.1056/NEJM199812173392501 -
Lack of Association of Guillain-Barre Syndrome With Vaccinations
This study found no evidence of an increased risk of Guillain-Barré syndrome following vaccinations, including influenza vaccines, based on a large retrospective analysis of cases from Kaiser Permanente Northern California.
DOI: 10.1093/cid/cit222 -
Guillain-Barré Syndrome and Vaccination: Usually Unrelated
A narrative review of epidemiological data on Guillain-Barré syndrome (GBS) and vaccines concludes that GBS is usually triggered by antecedent infections rather than vaccination; clear causal associations were limited to the obsolete neural-tissue rabies vaccine and the 1976 swi…
DOI: 10.1177/001857870003500214 -
Immunogenicity and safety of inactivated quadrivalent influenza vaccine compared with the trivalent vaccine for influenza infection: an overview of systematic reviews
Five systematic reviews find that inactivated quadrivalent influenza vaccines elicit higher immunogenicity than trivalent vaccines in settings with influenza B lineage mismatch across age groups, with safety comparable between them, though conclusions are tempered by methodologi…
DOI: 10.1186/s12879-023-08541-0